![]() | |
| Names | |
|---|---|
| Preferred IUPAC name
4-{4-(4-Fluorophenyl)-2-[4-(methanesulfinyl)phenyl]-1H-imidazol-5-yl}pyridine | |
| Other names
RWJ-64809; | |
| Identifiers | |
3D model (JSmol) |
|
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| ECHA InfoCard | 100.214.849 |
| EC Number |
|
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C21H16FN3OS | |
| Molar mass | 377.43 g/mol |
| Appearance | White to off-white solid |
| Solubility in DMSO | 50 mg/mL |
| Hazards | |
| GHS labelling: | |
![]() ![]() | |
| Danger | |
| H302, H318 | |
| P264, P270, P280, P301+P312, P305+P351+P338, P310, P330, P501 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references | |
SB 203580 is a specific inhibitor of p38α and p38β which suppresses downstream activation of MAPKAP kinase-2 and heat shock protein 27. At low concentrations, it does not inhibit JNK activity. SB-203580 was recently assigned the INN Adezamapimod, and is currently in phase 2 clinical trials to prevent post-operative tissue adhesion.
References
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.


